The panel will provide unique perspectives on the rapid growth of GLP-1 drugs and their potential to address the root causes of chronic diseases, such as obesity.
Details on the presentation are as follows:
Panel: The Future of GLP-1 Drugs – A Panacea for Chronic Disease?
Date: Wednesday, December 4, 2024, at 3:30 p.m. EST
Location: Convene One Boston Place
About Aphaia Pharma
Aphaia Pharma is a clinical-stage biopharmaceutical company harnessing proprietary precision-targeted drug formulations to restore endogenous hormone release from nutrient-sensing cells in the gastrointestinal tract to treat and prevent metabolic disorders such as obesity and associated diseases. Aphaia’s lead candidate, APH-012, a glucose formulation, has been shown to safely restore endogenous hormone release in individuals with obesity. APH-012 is being evaluated in two Phase 2 trials, one for chronic weight management in individuals with obesity and the second to improve glucose tolerance in individuals with prediabetes. The versatile design of Aphaia’s technology platform provides an opportunity for the development of treatments for multiple disease patterns.
Aphaia Investor Contact
Günter Jucho
Chief Financial Officer
jucho@aphaiapharma.com
Media Contact
Madelin Hawtin
LifeSci Communications
AphaiaPharma@lifescicomms.com